健友股份股票討論區

Nanjing King-Friend Biochemical PharmaceuticalLtd's strong financials and high ROE hint at future growth potential, despite recent share price drop. Its heavy reinvestment and profit-sharing commitment are positive, but future performance hinges on whether expected earnings growth is priced into the stock.

The P/E ratio suggests a less prosperous future for Nanjing King-Friend with an inferior earnings outlook as forecasted by analysts, which is causing shareholders to be uncomfortable. A significant surge in the share price is doubtful under these circumstances.